OR WAIT 15 SECS
The companies aim to advance research into inflammatory bowel disease.
On Dec. 3, 2018, TARGET PharmaSolutions, a privately held real-world data solutions company, announced that it has entered into a strategic partnership with Bristol Myers Squibb (BMS) for TARGET–IBD, an observational study that evaluates patients with inflammatory bowel disease (IBD). The study also includes adult and pediatric patients with ulcerative colitis, Crohn’s disease, and indeterminate colitis. The study is led by an academic steering committee co-chaired by Bruce Sands, MD (Mount Sinai), David Rubin, MD (University of Chicago), and Millie Long, MD (University of North Carolina).
“TARGET-IBD continues to collect valuable real-world data which enhances our understanding of the natural history of inflammatory bowel disease and the impact of different treatment paradigms on patient populations over time. The outcomes from real-world evidence can help doctors as they work to provide treatments to individual patients in real-life settings. This is particularly important given the ongoing innovation in the treatment of inflammatory bowel disease,” said Long in a company press release.
“The meticulously detailed real-world data it is collecting from [patients], such as severity of disease, is valuable for TARGET-IBD industry partners like BMS as they work to develop treatments to enhance patient outcomes. Our partnership demonstrates a shared vision of advancing IBD research and builds on our current partnership with Bristol-Myers Squibb for TARGET-NASH and TARGET-HCC,” said Meg Powell, CEO of TARGET PharmaSolutions, in the press release.
The TARGET-IBD study design is disease focused, not treatment-specific, allowing for continuous acquisition of natural history and outcomes data, including patient reported outcomes, as new treatments continue to enter the market and clinical programs evolve. It also includes a biorepository which its stakeholders can access for translational studies of viral resistance, genomics, and biomarkers to further their research of IBD.
Source: TARGET PharmaSolutions